Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 39.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,510 shares of the biopharmaceutical company’s stock after selling 36,175 shares during the period. Private Advisor Group LLC’s holdings in Gilead Sciences were worth $4,416,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Clearbridge Investments LLC grew its holdings in Gilead Sciences by 179.0% during the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after acquiring an additional 2,915,141 shares in the last quarter. abrdn plc increased its holdings in Gilead Sciences by 89.0% in the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after buying an additional 1,772,887 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Gilead Sciences during the fourth quarter valued at approximately $133,584,000. AEGON ASSET MANAGEMENT UK Plc bought a new position in Gilead Sciences during the 4th quarter worth approximately $63,971,000. Finally, Van ECK Associates Corp increased its holdings in shares of Gilead Sciences by 18.3% in the 3rd quarter. Van ECK Associates Corp now owns 4,534,839 shares of the biopharmaceutical company’s stock valued at $339,841,000 after acquiring an additional 702,342 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. TD Cowen dropped their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Barclays decreased their target price on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Finally, Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and cut their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $83.69.

Gilead Sciences Trading Down 0.5 %

Shares of GILD opened at $64.58 on Friday. The business’s 50-day moving average price is $70.09 and its 200 day moving average price is $75.52. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $80.41 billion, a P/E ratio of 179.39, a P/E/G ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 1-year low of $64.33 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period last year, the firm posted $1.37 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.77%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.